Safinamide NDA Re-Submitted To The US FDA

Safinamide New Drug Application (NDA) Re-submitted to the US Food and Drug Administration (FDA).Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

More:
www.prnewswire.com/news-releases/safinamide-new-drug-application-nda-re-submitted-to-the-us-food-and-drug-administration-fda-286985731.html